Pathophysiology and current understanding of degenerative disc disease

Table 1 Summary of normal anatomy and physiology of intervertebral disc

Component	Structure	Primary function	Key features
AF	Concentric collagen lamellae; outer AF rich in type I collagen, inner AF rich in type II	Resists tensile/shear forces; contains NP	Limited vascularity; provides circumferential strength
NP	Hydrated, proteoglycan-rich gel (high aggrecan/GAG content)	Generates hydrostatic pressure; absorbs compressive loads	Completely avascular; maintains hydration-dependent load distribution
CEPs	Thin hyaline cartilage layers between disc and vertebrae	Nutrient and metabolite diffusion	Primary route of nutrient/waste exchange via subchondral capillaries
Vascular supply	NP and inner AF avascular; CEP-adjacent capillary network	Diffusion-based nutrient support	Low metabolic turnover; vulnerable to hypoxia and nutrient limitation
Cellular activity	Sparse disc cells regulating ECM turnover	Maintains ECM integrity and hydration	Low metabolic reserve; sensitive to mechanical and metabolic stress
Biomechanical function	Integrated AF-NP-CEP system	Distributes compressive, tensile, and shear forces	Depends on hydration, ECM turnover, and cell viability
Vulnerabilities	Avascular, hypoxic microenvironment	Predisposed to degeneration if homeostasis fails	Risk increases with aging, mechanical load, and metabolic stress

AF: Annulus fibrosus; NP: Nucleus pulposus; CEP: Terminal endplate; GAG: Glycosaminoglycans; ECM: Extracellular matrix.

Table 2 Multifactorial mechanisms of intervertebral disc degeneration

Category	Key mechanisms	Consequences for IVD	Representative factors
Mechanical stress and load	Repetitive microtrauma to AF and NP. Collagen/elastin disorganization. Loss of NP hydration. Altered biomechanics → increased shear forces	Decreased disc height. Structural failure. Instability. Herniation and nerve compression	Heavy labor, torsion, bending, vibration exposure
Genetic and environmental factors	SNPs affecting ECM proteins and inflammatory mediators. Altered ECM synthesis or stability. Epigenetic changes due to lifestyle factors	Early weakening of ECM. Increased inflammatory signaling. Catabolic microenvironment	Gene variants (COL1A1, COL9A2, ACAN, IL-1, IL-6), smoking, obesity, vibration, repetitive loading
Nutrition and metabolism	Impaired nutrient diffusion across CEP. Local hypoxia + acidic microenvironment. Accumulation of AGEs. Oxidative stress and systemic metabolic dysregulation	Reduced cell viability. Inhibited proteoglycan synthesis. ECM stiffening. Impaired permeability and degeneration	Endplate calcification, atherosclerosis, diabetes, metabolic syndrome, obesity
Cellular senescence	Oxidative stress, DNA damage, mitochondrial dysfunction. SASP production: Proinflammatory cytokines, MMPs, ADAMTS. NF-κB and p38 MAPK activation	ECM degradation. Increased inflammation. Loss of regenerative capacity. Accumulation of non-functional cells	Increased ROS, mitochondrial dysfunction, SASP factors (IL-1β, IL-6, TNF-α), MMPs, ADAMTS
Aging and microenvironment	Loss of proteoglycans and GAGs → decreased hydration. Increased collagen cross-linking, fragmentation. CEP calcification and sclerosis. Accumulation of waste products	Reduced elasticity and load-distribution. Hypoxia and acidity. Increased apoptosis and catabolism. Progressive irreversible degeneration	Age-related CEP thickening, decreased metabolic activity, reduced nutrient diffusion
Lifestyle and comorbidities	Smoking-induced hypoxia. Obesity increasing axial load. Sedentary behavior reducing beneficial mechanical stimuli. Metabolic disorders increasing AGEs	Oxidative stress. Matrix degradation. Increased stiffness and reduced tensile strength. Accelerated degeneration	Smoking, obesity, poor posture, inactivity, diabetes

IVD: Intervertebral disc; AF: Annulus fibrosus; NP: Nucleus pulposus; CEP: Terminal endplate; ECM: Extracellular matrix; SNPs: Single-nucleotide polymorphisms; COL: Collagen; ACAN: Aggrecan; IL: Interleukins; AGEs: Advanced glycosylation end products; ROS: Reactive oxygen species; SASP: Senescence-associated secretory phenotype; TNF-α: Tumor necrosis factor alpha; MMPs: Matrix metalloproteinases; ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs; MAPK: Mitogen-activated protein kinase; GAG: Glycosaminoglycan; NF-κB: Nuclear factor kappa B.

Table 3 Key structural, biomechanical, and biochemical consequences of degenerative disc disease

Entity	Primary changes	Main effects
Disc structure	Loss of height; dehydration; proteoglycan decline	Reduced hydrostatic pressure; impaired load absorption
Load redistribution	Increased loading of posterior elements	Facet joint degeneration; ligamentous strain
Spine stability	Segmental hypermobility; altered vertebral coupling	Mechanical instability; deformity (e.g., spondylolisthesis)
Spinal canal and foraminal anatomy	Ligamentum flavum hypertrophy; capsule thickening	Spinal/foraminal stenosis; nerve-root compression
Biochemical milieu	↑ Prostaglandins, nitric oxide, IL-1β, TNF-α	Nociceptor sensitization; chronic inflammation
Neural changes	Ingrowth of nociceptors + neovascularization	Discogenic pain; increased mechanical sensitivity
Overall outcome	Interaction of mechanical + inflammatory factors	Chronic pain, reduced mobility, progressive dysfunction

IL-1β: Interleukin 1beta; TNF-α: Tumor necrosis factor alpha.

Table 4 Therapeutic options in degenerative disc disease

Category	Therapy	Main features	Benefits and limitations
Conservative management	Physical therapy. Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Strengthens core and paraspinal muscles. Improves posture and flexibility	Reduces mechanical strain. First-line therapy. Requires adherence
	Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Addresses modifiable risk factors	Slows degeneration. Non-invasive. Patient-dependent
	Pharmacological therapy (NSAIDs, muscle relaxants, analgesics)	NSAIDs ↓ COX activity and prostaglandins. Analgesics reduce pain	Short-term relief; risks include gastrointestinal, renal, cardiovascular side effects
Medical pain management	NSAIDs	Anti-inflammatory via COX inhibition	Short-term relief. Limited disc penetration. Systemic risks
	Opioids	Activate G-protein coupled receptor pathways → inhibit neurotransmission	Effective for severe pain. High risk of addiction and dependence
	Muscle relaxants	Reduce muscle spasm	Symptomatic relief. Sedation risk
	Epidural corticosteroid injections	Reduce inflammation via COX and arachidonic acid inhibition	Temporary relief. Systemic steroid effects. No long-term benefit
Emerging pharmacologic therapies	Pamidronate	Bisphosphonate inhibiting osteoclasts and bone turnover	Potential pain reduction. Investigational
	Abaloparatide	Osteoporosis drug shown to reduce IVD degeneration (animal models)	Experimental. No established human benefit
	Alpha-2-macroglobulin	Protease inhibitor targeting FAC	Under investigation for slowing degeneration
Surgical management	Discectomy and decompression	Removes herniated disc tissue → relieves nerve compression	Effective for stenosis/herniation. Does not halt degeneration
	Spinal fusion	Removes disc → inserts cage + hardware. Eliminates motion	Pain reduction. Decreases mobility. Adjacent segment disease
	Total disc replacement	Replaces disc with motion-preserving prosthesis	Preserves mobility. Modest benefits vs fusion. Long-term data limited
Biological and regenerative therapies	Platelet-rich plasma	Growth factors (PDGF, VEGF, IGF-1, TGF-β) stimulate ECM synthesis	Promising early results. Inconsistent human data. No standardized protocols available
	Stem cell therapies	Implantation of regenerative cells into disc to restore ECM and hydration	Early promise. Challenges: Cell survival; microenvironment; delivery
	Growth factor therapy (TGF-β, BMP-7)	Enhances matrix production	Experimental. Limited human evidence
	Gene therapy	Introduces genes to enhance matrix synthesis or reduce catabolism	Highly experimental. Delivery and safety challenge

NSAID: Nonsteroidal anti-inflammatory drugs; COX: Cyclooxygenase; IVD: Intervertebral disc; FAC: Fibronectin-aggrecan complex; PDGF: Platelet-derived growth factor; VEGF: Vascular endothelial growth factor; IGF-1: Insulin-like growth factor 1; TGF-β: Transforming growth factor-β; ECM: Extracellular matrix; BMP-7: Bone morphogenetic protein 7.